GLP-1 and Underlying Beneficial Actions in Alzheimer’s Disease, Hypertension, and NASH
GLP-1 is derived from intestinal L cells, which takes effect through binding to GLP-1R and is inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4). Since its discovery, GLP-1 has emerged as an incretin hormone for its facilitation in insulin release and reduction of insulin resistance (IR). Howe...
Main Authors: | Qiu-Xuan Li, Han Gao, Yue-Xin Guo, Bo-Ya Wang, Rong-xuan Hua, Lei Gao, Hong-Wei Shang, Xin Lu, Jing-Dong Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2021.721198/full |
Similar Items
-
Glucagon-like peptide-1 (GLP-1) mediates the protective effects of dipeptidyl peptidase IV inhibition on pulmonary hypertension
by: Jingjing Wang, et al.
Published: (2019-01-01) -
DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs
by: Jianqiang Zhang, et al.
Published: (2019-05-01) -
GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimer's disease
by: Jiaping Zheng, et al.
Published: (2021-05-01) -
DPP-4 inhibition enhanced renal tubular and myocardial GLP-1 receptor expression decreased in CKD with myocardial infarction
by: Seung Jung Kim, et al.
Published: (2019-03-01) -
Targeting the DPP-4-GLP-1 pathway improves exercise tolerance in heart failure patients: a systematic review and meta-analysis
by: Chengcong Chen, et al.
Published: (2019-12-01)